Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Bristol-Myers Squibb Co (NYSE:BMY)

70.61
Delayed Data
As of Jun 24
 -2.03 / -2.79%
Today’s Change
51.82
Today|||52-Week Range
75.12
+2.65%
Year-to-Date
Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
Jun 24 / Zacks.com - Paid Partner Content
Endo's (ENDP) Pain Drug Opana ER to Face FDA Panel in Fall
Jun 16 / Zacks.com - Paid Partner Content
Why Investors Are Paying a Premium for These 3 Drugmakers
Jun 24 / MotleyFool.com - Paid Partner Content
Combat Volatility with These 5 Low Beta Stocks
Jun 16 / Zacks.com - Paid Partner Content
Incyte Reports Epacadostat Combination Study Initiation
Jun 23 / Zacks.com - Paid Partner Content
Novo Nordisk (NVO) Reports Positive Trial Results on Victoza
Jun 15 / Zacks.com - Paid Partner Content
GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
Jun 22 / Zacks.com - Paid Partner Content
Better Buy: Johnson & Johnson vs. Eli Lilly
Jun 15 / MotleyFool.com - Paid Partner Content
Cramer: Let's Put Brexit in Its Historic Context
Jun 22 / TheStreet.com - Paid Partner Content
Jazz Pharmaceuticals Offers HAL Study Data on JZP-110
Jun 15 / Zacks.com - Paid Partner Content
RedHill (RDHL) Stock Up on Positive Phase I Data on Yeliva
Jun 22 / Zacks.com - Paid Partner Content
Infinity (INFI) at 52-Week Low on Disappointing Duvelisib Data
Jun 15 / Zacks.com - Paid Partner Content
7 Profitable Medical Stocks Ranked as Buys Now
Jun 21 / Zacks.com - Paid Partner Content
Zacks Industry Rank Analysis Highlights: Pfizer, Bristol-Myers Squibb and H Lundbeck
Jun 15 / Zacks.com - Paid Partner Content
3 Ways This $30 Billion Market Is Bristol's for the Taking
Jun 21 / MotleyFool.com - Paid Partner Content
Will Bristol-Myers Squibb (BMY) Crush Estimates at Its Next Earnings Report?
Jun 15 / Zacks.com - Paid Partner Content
Gilead Presents Favorable Preliminary Bictegravir HIV Data
Jun 21 / Zacks.com - Paid Partner Content
ARIAD (ARIA) Presents Long-Term Phase II Data on Iclusig
Jun 14 / Zacks.com - Paid Partner Content
Vical (VICL) Reports Phase I/II Data on Genital Herpes Vaccine
Jun 21 / Zacks.com - Paid Partner Content
Shire Gets Breakthrough Status for Rare Disease Candidates
Jun 14 / Zacks.com - Paid Partner Content
Glaxo/Innoviva's Closed Triple Combination Tops Phase III
Jun 21 / Zacks.com - Paid Partner Content
Merck's Biosimilar Version of Lantus Tops Phase III Studies
Jun 14 / Zacks.com - Paid Partner Content
Epizyme Offers Early Data on Non-Hodgkin Lymphoma Drug
Jun 20 / Zacks.com - Paid Partner Content
Abbott Labs (ABT) Reports Positive Data on FreeStyle Libre
Jun 14 / Zacks.com - Paid Partner Content
3 Finds in Biotech's 'Pocket of Value'
Jun 20 / TheStreet.com - Paid Partner Content
Don't Make It Complicated, Own Drug Stocks
Jun 14 / Zacks.com - Paid Partner Content
Auris (EARS) Begins Phase III Study for Sudden Deafness
Jun 20 / Zacks.com - Paid Partner Content
Revance's Lead Candidate Fails in Phase III Crow's Feet Study
Jun 14 / Zacks.com - Paid Partner Content
Emergent (EBS) BioThrax sBLA Accepted for FDA Review
Jun 20 / Zacks.com - Paid Partner Content
Amgen's Biosimilar of AbbVie's Humira to Face FDA Panel
Jun 14 / Zacks.com - Paid Partner Content
3 Top Big Pharma Stocks to Buy Now
Jun 19 / MotleyFool.com - Paid Partner Content
Marinus Stock Down on Dismal Phase III Data on Ganaxolone
Jun 14 / Zacks.com - Paid Partner Content
Kura (KURA) Begins Dosing in Phase II Study on Cancer Drug
Jun 17 / Zacks.com - Paid Partner Content
Forget Growth; Focus on Earnings Beat with These 4 Stocks
Jun 14 / Zacks.com - Paid Partner Content
Medivation's (MDVN) Pidilizumab Positive in Phase I/II Study
Jun 17 / Zacks.com - Paid Partner Content
5 Things Organovo Holdings, Inc. Management Wants You to Know
Jun 13 / MotleyFool.com - Paid Partner Content
Zacks.com featured highlights: B&G Foods, J. M. Smucker, Bristol-Myers Squibb, Pretiu...
Jun 17 / Zacks.com - Paid Partner Content
Agios Reports Favorable Phase II PK Deficiency Study Data
Jun 13 / Zacks.com - Paid Partner Content
Allergan Glaucoma Gel Stent Filing Accepted for FDA Review
Jun 17 / Zacks.com - Paid Partner Content
Pfizer Reveals Final Phase III Data on Inotuzumab Ozogamicin
Jun 13 / Zacks.com - Paid Partner Content
Don't Make it Complicated, Own Drug Stocks
Jun 16 / Zacks.com - Paid Partner Content
Allied Minds: The search for fortune and glory
Jun 08 / FT.com - Paid Partner Content
Merck & Co., Inc. Wins This Round of the Immunotherapy Lung-Cancer Battle
Jun 16 / MotleyFool.com - Paid Partner Content
Price of cancer drugs vastly higher in US, according to study
Jun 06 / FT.com - Paid Partner Content
Stock Market News for June 16, 2016
Jun 16 / Zacks.com - Paid Partner Content
President raises patient and business hope for cancer treatment
Jun 02 / FT.com - Paid Partner Content
Emergent (EBS) BioThrax Gets Orphan Status in the U.S.
Jun 16 / Zacks.com - Paid Partner Content